Skip to main content
. Author manuscript; available in PMC: 2018 Feb 9.
Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Dec 27;7(4):487–493. doi: 10.1016/j.cgh.2008.12.018

Table 1.

Characteristics of studies included in the analysis.

Author Year Country Type
of
study		 Number
of
patients
Rx
group		 Medication
Rx Group		 Number
of
patients
placebo
group		 Medication
Placebo
Group		 Study
design		 Blinding Randomization
method
reported		 Allocation
concealment
(Yes/no)		 Sample size
calculations
in
manuscript
(Yes/no)		 Intention
to
treat
analysis
(Yes/no)		 Mean
Follow-
up
(weeks)
Rx
Group		 Mean
Follow-
up
(weeks)
Placebo
Group
Terg23 2008 Argentina Multi- center 50 Ciprofloxacin 500 mg /day 50 Placebo pills RCT Double-blind Yes No Yes Yes 31 ±18 30 ±18
Novella22 1997 Spain Multi-center 56 Norfloxacin 400 mg/day 53 Norfloxacin 400 mg/day only when hospitalized RCT Single-blind Yes No No Yes 47 ± 5 40 ± 5
Grange21 1998 France Multi- center 53 Norfloxacon 400 mg/day 54 Placebo pills RCT Single- blind No Yes (identical Norfloxacin and placebo pills) Yes Yes 18 ± 10 19 ± 10
Fernandez20 2007 Spain Single- center 35 Norfloxacin 400 mg/day 33 Placebo pills RCT Single- blind Yes Yes (identical Norfloxacin and placebo pills) Yes Yes 52# 52#

Abbreviations: Rx, treatment; RCT, randomized-controlled trial

#

equivalent to 1 year